Advances in the treatment of autism spectrum disorder: Wharton jelly mesenchymal stem cell transplantation

doi:10.5662/wjm.v15.i1.95857

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1935)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

HTML

1193

Figures (1-3)

185

Tables (1-1)

183

Sum=1608

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

189

Sum=243

Mar 20, 2025 (publication date) through Feb 21, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Methodology

ISSN

2222-0682

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Methodol. Mar 20, 2025; 15(1): 95857
Published online Mar 20, 2025. doi: 10.5662/wjm.v15.i1.95857

Full Size Figure Download Figure

Figure 1 Wharton’s jelly-derived mesenchymal stem cell flow cytometry. Positive marker values (cluster of differentiation [CD]90, CD105, CD73 and CD44) are above 95%. Negative marker values (CD45, CD34, CD19, CD11B, human leukocyte antigen-DR and CD14) are below 2%. HLA: Human leukocyte antigen[8]. Citation: Boyalı O, Kabatas S, Civelek E, Ozdemir O, Bahar-Ozdemir Y, Kaplan N, Savrunlu EC, Karaöz E. Allogeneic mesenchymal stem cells may be a viable treatment modality in cerebral palsy. World J Clin Cases 2024; 12: 1585-1596. Copyright © The Authors 2024. Published by Baishideng Publishing Group Inc.

Citation: Kabatas S, Civelek E, Savrunlu EC, Karaaslan U, Yıldız Ö, Karaöz E. Advances in the treatment of autism spectrum disorder: Wharton jelly mesenchymal stem cell transplantation. World J Methodol 2025; 15(1): 95857
URL: https://www.wjgnet.com/2222-0682/full/v15/i1/95857.htm
DOI: https://dx.doi.org/10.5662/wjm.v15.i1.95857